Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00650572 | A Study of ARRY-380 in Patients With Advanced HER2+ Cancer | PHASE1 | COMPLETED | 50 | — | — | May 1, 2008 | Mar 1, 2013 | May 7, 2020 | 4 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| ARRY-380 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-380, HER2 inhibitor; oral | DRUG | Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule. |
Key Inclusion Criteria (Part 1 and Part 2): * Histological or cytological evidence of HER2+ cancer (Part 1) or HER2+ metastatic breast cancer (Part 2). * Patients should have received at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standar...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |